CRSP Earnings

Quarterly EPS
$-1.01
Q3 2024
$-0.44
Q4 2024
$-1.58
Q1 2025
$-2.40
Q2 2025
$-1.17
Q3 2025
$-1.37
Q4 2025
$-1.28
Q1 2026
$-0.94
Q2 2026
Latest Revenue10.2M
Latest Net Income-91154000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.9410.2M-91154000+1,041.4%+60.8%
Q1 2026-$1.281.5M-122931000+68.6%+19.0%
Q4 2025-$1.37864.0K-130613000-97.6%-211.4%
Q3 2025-$1.17889.0K-106441000+47.7%-15.8%
Q2 2025-$2.40892.0K-208549000+72.5%-61.1%
Q1 2025-$1.58865.0K-135996000+71.6%-10.5%
Q4 2024-$0.4435.7M-37311000-82.3%-139.3%
Q3 2024-$1.01602.0K-85942000+28.4%
Q2 2024-$1.49517.0K-126408000
Q1 2024-$1.43504.0K-116591000
Q4 2023$1.12201.2M89.3M
Q3 2023-$1.410-112152000
CRISPR Therapeutics (CRSP) — Earnings